This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Overgaard, J. Search for Related Content PubMed PubMed Citation Articles by Overgaard, J. Social Bookmarking                            What's this?

Hypoxic Radiosensitization: Adored and Ignored

Jens Overgaard

From the Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark

Address reprint requests to Jens Overgaard, MD, DMSc, Department of Experimental Clinical Oncology, Aarhus University Hospital, Nørrebrogade 44, Bldg 5, DK-8000 Aarhus C, Denmark; e-mail: jens{at}oncology.dk

Since observations from the beginning of the last century, it has become well established that solid tumors may contain oxygen-deficient hypoxic areas and that cells in such areas may cause tumors to become radioresistant. Identifying hypoxic cells in human tumors has improved by the help of new imaging and physiologic techniques, and a substantial amount of data indicates the presence of hypoxia in many types of human tumors, although with a considerable heterogeneity among individual tumors. Controlled clinical trials during the last 40 years have indicated that this source of radiation resistance can be eliminated or modified by normobaric or hyperbaric oxygen or by the use of nitroimidazoles as hypoxic radiation sensitizers. More recently, attention has been given to hypoxic cytotoxins, a group of drugs that selectively or preferably destroys cells in a hypoxic environment. An updated systematic review identified 10,108 patients in 86 randomized trials designed to modify tumor hypoxia in patients treated with curative attempted primary radiation therapy alone. Overall modification of tumor hypoxia significantly improved the effect of radiotherapy, with an odds ratio of 0.77 (95% CI, 0.71 to 0.86) for the outcome of locoregional control and with an associated significant overall survival benefit (odds ratio = 0.87; 95% CI, 0.80 to 0.95). No significant influence was found on the incidence of distant metastases or on the risk of radiation-related complications. Ample data exist to support a high level of evidence for the benefit of hypoxic modification. However, hypoxic modification still has no impact on general clinical practice.

Author's disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Q.-T. X. Le, J. Moon, M. Redman, S. K. Williamson, P. N. Lara Jr, Z. Goldberg, L. E. Gaspar, J. J. Crowley, D. F. Moore Jr, and D. R. Gandara Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: SWOG 0222 J. Clin. Oncol., June 20, 2009; 27(18): 3014 - 3019. [Abstract] [Full Text] [PDF]

				P. Lassen, J. G. Eriksen, S. Hamilton-Dutoit, T. Tramm, J. Alsner, and J. Overgaard Effect of HPV-Associated p16INK4A Expression on Response to Radiotherapy and Survival in Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., April 20, 2009; 27(12): 1992 - 1998. [Abstract] [Full Text] [PDF]

				P WARDMAN The importance of radiation chemistry to radiation and free radical biology (The 2008 Silvanus Thompson Memorial Lecture) Br. J. Radiol., February 1, 2009; 82(974): 89 - 104. [Abstract] [Full Text] [PDF]

				T. A. Beerman, L. S. Gawron, S. Shin, B. Shen, and M. M. McHugh C-1027, A Radiomimetic Enediyne Anticancer Drug, Preferentially Targets Hypoxic Cells Cancer Res., January 15, 2009; 69(2): 593 - 598. [Abstract] [Full Text] [PDF]